Nazara Tech: CARE Ratings Confirms No Deviation in Warrants Utilisation

Nazara Technologies Ltd has received a Monitoring Agency Report from CARE Ratings Limited for the quarter ended June 30, 2026. The report, issued in accordance with SEBI regulations, confirms that there has been no deviation in the utilization of proceeds raised through a preferential issue of 1,82,31,000 warrants. These warrants were convertible into equity shares at ₹260 per share, aggregating to ₹500.006 crore. The monitoring agency has verified the utilization of funds against the specified objects of the issue, as per the agreement dated March 30, 2026. CARE Ratings has declared that the report provides an objective view based on information provided by the issuer and other reliable sources, while also clarifying its role does not constitute an audit or independent verification.